Tradestie Institutional Equity Comparison Engine
DRMA vs OKYO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
OKYO Overall Edge
OKYO Captures Institutional Edge (2โ0 Pillars ยท 5โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to OKYO Pharma Limited Ordinary Shares (OKYO) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, DRMA trades at N/M Forward P/E with -13082.3% operating margin (+0.0% YoY revenue) versus OKYO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, DRMA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against OKYO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
DRMA N/M vs OKYO N/M Fwd P/E
Growth & Margin Winner
OKYO
Op Margin -13082.3% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner
OKYO
1Y -79.1% vs -47.0% ยท 52W Pos 0% vs 3%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
DRMA
NASDAQ
Dermata Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.51
-4.23% 1D
Market Cap
$2.6M
1M Return
-41.03%
1Y Return
-79.12%
Forward P/E
N/M
Unified AI Score
42.2 / 100
HOLD
Tech 35.0
Fund 42.0
Flow 50.0
Mom 55.0
OKYO
NASDAQ
OKYO Pharma Limited Ordinary Shares
Biological Products, (No Diagnostic Substances)
$1.07
-7.76% 1D
Market Cap
$62.7M
1M Return
-27.21%
1Y Return
-47.03%
Forward P/E
N/M
Unified AI Score
42.8 / 100
HOLD
Tech 38.0
Fund 54.0
Flow 50.0
Mom 45.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
DRMA -79.12%
OKYO -47.03%
Spread: +32.09 pp (OKYO Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
DRMA TTM Op. Margin: -13082.3%
OKYO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DRMA vs OKYO. Trailing 12-month operating profitability (DRMA -13082.3% vs OKYO 0.0%) and valuation multiples (DRMA N/M vs OKYO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | DRMA | OKYO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.6M | $62.7M | Larger Scale | OKYO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | -13082.3% | 0.0% | Higher Margin | OKYO |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -241.5% | -263.8% | Higher ROE | DRMA |
| 52-Week Range Position Momentum | 0% ($0โ$5) | 3% ($1โ$3) | Stronger Trend | OKYO |
| Beta / 30D Volatility Risk Regime | 1.09ฮฒ ยท 105% Vol | 1.00ฮฒ ยท 76% Vol | Lower Realized Risk | OKYO |
| Unified Institutional Score Composite Signal | 42.2 / 100 (HOLD) | 42.8 / 100 (HOLD) | Higher Composite | OKYO |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full DRMA vs OKYO Buy Guide
DRMA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
OKYO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither DRMA nor OKYO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.